50,000 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Acquired by Maven Securities LTD

Maven Securities LTD bought a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 50,000 shares of the company’s stock, valued at approximately $1,223,000. Maven Securities LTD owned approximately 0.06% of Myriad Genetics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its holdings in Myriad Genetics by 7.9% during the second quarter. Point72 Asset Management L.P. now owns 839,456 shares of the company’s stock worth $20,533,000 after purchasing an additional 61,260 shares in the last quarter. Disciplined Growth Investors Inc. MN increased its stake in shares of Myriad Genetics by 0.5% during the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 2,087,328 shares of the company’s stock worth $51,056,000 after purchasing an additional 10,035 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Myriad Genetics in the second quarter valued at $221,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Myriad Genetics in the second quarter valued at approximately $2,315,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Myriad Genetics by 9.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 50,071 shares of the company’s stock worth $1,225,000 after purchasing an additional 4,528 shares during the period. Institutional investors and hedge funds own 99.02% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on MYGN. Scotiabank upped their price objective on Myriad Genetics from $29.00 to $34.00 and gave the stock a “sector outperform” rating in a report on Tuesday, August 13th. TD Cowen raised their price objective on Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. upped their price objective on Myriad Genetics from $17.00 to $20.00 and gave the company an “underweight” rating in a research note on Wednesday, August 7th. Morgan Stanley started coverage on shares of Myriad Genetics in a report on Thursday, September 19th. They issued an “equal weight” rating and a $32.00 price target for the company. Finally, Piper Sandler increased their target price on Myriad Genetics from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 13th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.91.

Insider Activity

In other Myriad Genetics news, Director Colleen F. Reitan sold 46,012 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the sale, the director now directly owns 42,533 shares of the company’s stock, valued at $1,188,797.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Myriad Genetics news, Director Heinrich Dreismann sold 10,000 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $27.05, for a total transaction of $270,500.00. Following the transaction, the director now owns 121,648 shares in the company, valued at approximately $3,290,578.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Colleen F. Reitan sold 46,012 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $27.95, for a total value of $1,286,035.40. Following the transaction, the director now owns 42,533 shares in the company, valued at approximately $1,188,797.35. The disclosure for this sale can be found here. 2.10% of the stock is owned by corporate insiders.

Myriad Genetics Stock Down 1.3 %

Shares of MYGN opened at $27.03 on Wednesday. The business’s 50 day simple moving average is $27.44 and its 200-day simple moving average is $24.36. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.78. The company has a market capitalization of $2.45 billion, a P/E ratio of -9.59 and a beta of 1.92. Myriad Genetics, Inc. has a one year low of $13.82 and a one year high of $29.30.

Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, August 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Myriad Genetics had a negative net margin of 19.35% and a negative return on equity of 5.64%. The firm had revenue of $211.50 million during the quarter, compared to analyst estimates of $206.44 million. During the same quarter in the previous year, the business earned ($0.21) EPS. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. As a group, sell-side analysts predict that Myriad Genetics, Inc. will post -0.35 EPS for the current fiscal year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.